A Double-Blind, Placebo-Controlled, Crossover Pilot Trial With Extension Using an Oral Mucosal Cannabinoid Extract for Treatment of Chemotherapy-Induced Neuropathic Pain
- 1 January 2014
- journal article
- research article
- Published by Elsevier BV in Journal of Pain and Symptom Management
- Vol. 47 (1), 166-173
- https://doi.org/10.1016/j.jpainsymman.2013.02.018
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Cannabinoid Type-1 Receptor Reduces Pain and Neurotoxicity Produced by ChemotherapyJournal of Neuroscience, 2012
- Cannabinoids as Pharmacotherapies for Neuropathic Pain: From the Bench to the BedsideNeurotherapeutics, 2009
- Selective Activation of Cannabinoid CB2 Receptors Suppresses Neuropathic Nociception Induced by Treatment with the Chemotherapeutic Agent Paclitaxel in RatsJournal of Pharmacology and Experimental Therapeutics, 2008
- Activation of cannabinoid CB1 and CB2 receptors suppresses neuropathic nociception evoked by the chemotherapeutic agent vincristine in ratsBritish Journal of Pharmacology, 2007
- Altered discharges of spinal wide dynamic range neurons and down-regulation of glutamate transporter expression in rats with paclitaxel-induced hyperalgesiaNeuroscience, 2005
- Activation of Cannabinoid CB2Receptors Suppresses C-Fiber Responses and Windup in Spinal Wide Dynamic Range Neurons in the Absence and Presence of InflammationJournal of Neurophysiology, 2004
- Taxol-induced sensory disturbance is characterized by preferential impairment of myelinated fiber function in cancer patientsPain, 2004
- Changes in sensory processing in the spinal dorsal horn accompany vincristine-induced hyperalgesia and allodyniaPain, 2003
- Chemotherapy-evoked Painful Peripheral NeuropathyPain Medicine, 2001
- Neurologic complications of cancer therapyCurrent Treatment Options in Neurology, 1999